Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

Model scores of the 29,894 trials active now.

Model score 14% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (607 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: radiationtumorchemotherapychildrenimaging
  Phrases that lowered it: patientsdiagnosedcombinationparticipatereceived
• Sponsor's past termination rate: 1.6% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 18.7% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 4 (lowers risk) · Design
• Drug's FAERS reports before start: 85016 (lowers risk) · Drug's FDA history
• Minimum age: 1 (lowers risk) · Who can join
• Sponsor's past trials: 61 (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 11 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 17567 (lowers risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 9 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Maximum age: 21 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma NCT01088035 · started 2010 · scored riskier than 98% of active trials terminated
• Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma NCT02774421 · started 2017 · scored riskier than 33% of active trials completed
• Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors NCT02684071 · started 2016 · scored riskier than 69% of active trials terminated
• Carboplatin and Bevacizumab for Recurrent Ependymoma NCT01295944 · started 2011 · scored riskier than 61% of active trials completed
• Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma NCT01032070 · started 2010 · scored riskier than 93% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.